Abstract
Spliceosome-mediated mRNA trans-splicing (SMaRT) is a promising strategy for treatment of genetic diseases which cannot be targeted via classical therapy approaches. SMaRT utilizes an exogenous pre-mRNA trans-splicing molecule (PTM) to correct a diseased target pre-mRNA. This process relies on splicing of two separate pre-mRNA molecules in trans creating a mature chimeric mRNA molecule which consists of the protein coding sequence of the PTM as well as the endogenous mRNA. For therapeutic implications, the most critical step in SMaRT is to develop PTMs resulting in a high ratio of trans-splicing to regular cis-splicing.
This protocol provides guidelines on how to design PTMs and describes a fast screening assay to test their efficiencies. To elucidate the therapeutic potential of the best candidates in a more native setting, these PTMs are tested further on mini genes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wu Z, Yang H, Colosi P (2010) Effect of genome size on AAV vector packaging. Mol Ther 18(1):80–86
Olsson JE et al (1992) Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 9(5):815–830
Puttaraju M et al (1999) Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat Biotechnol 17(3):246–252
Berger A et al (2016) mRNA trans-splicing in gene therapy for genetic diseases. Wiley Interdiscip Rev RNA 7(4):487–498
Dooley SJ et al (2018) Spliceosome-mediated pre-mRNA trans-splicing can repair CEP290 mRNA. Mol Ther Nucleic Acids 12:294–308
Berger A et al (2015) Repair of rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new approach for autosomal dominant retinitis pigmentosa. Mol Ther 23(5):918–930
Mearini G et al (2013) Repair of Mybpc3 mRNA by 5′-trans-splicing in a mouse model of hypertrophic cardiomyopathy. Mol Ther Nucleic Acids 2:e102
Lorain S et al (2013) Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches. Nucleic Acids Res 41(17):8391–8402
Brent MR, Guigo R (2004) Recent advances in gene structure prediction. Curr Opin Struct Biol 14(3):264–272
Mansfield SG et al (2003) 5′ exon replacement and repair by spliceosome-mediated RNA trans-splicing. RNA 9(10):1290–1297
Gruber C et al (2011) Spliceosome-mediated RNA trans-splicing facilitates targeted delivery of suicide genes to cancer cells. Mol Cancer Ther 10(2):233–241
Murauer EM et al (2013) A reporter-based screen to identify potent 3′ trans-splicing molecules for endogenous RNA repair. Hum Gene Ther Methods 24(1):19–27
Dallinger G et al (2003) Development of spliceosome-mediated RNA trans-splicing (SMaRT) for the correction of inherited skin diseases. Exp Dermatol 12(1):37–46
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Riedmayr, L.M. (2020). SMaRT for Therapeutic Purposes. In: Li, H., Elfman, J. (eds) Chimeric RNA. Methods in Molecular Biology, vol 2079. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9904-0_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9904-0_17
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9903-3
Online ISBN: 978-1-4939-9904-0
eBook Packages: Springer Protocols